176 related articles for article (PubMed ID: 10485489)
1. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate.
Boerman OC; Kranenborg MH; Oosterwijk E; Griffiths GL; McBride WJ; Oyen WJ; de Weijert M; Oosterwijk-Wakka J; Hansen HJ; Corstens FH
Cancer Res; 1999 Sep; 59(17):4400-5. PubMed ID: 10485489
[TBL] [Abstract][Full Text] [Related]
2. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
[TBL] [Abstract][Full Text] [Related]
3. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
[TBL] [Abstract][Full Text] [Related]
4. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
[TBL] [Abstract][Full Text] [Related]
5. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
[TBL] [Abstract][Full Text] [Related]
6. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.
Karacay H; McBride WJ; Griffiths GL; Sharkey RM; Barbet J; Hansen HJ; Goldenberg DM
Bioconjug Chem; 2000; 11(6):842-54. PubMed ID: 11087333
[TBL] [Abstract][Full Text] [Related]
7. Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies.
Kranenborg MH; Boerman OC; Oosterwijk-Wakka JC; de Weijert MC; Corstens FH; Oosterwijk E
Int J Cancer; 1998 Jan; 75(1):74-80. PubMed ID: 9426693
[TBL] [Abstract][Full Text] [Related]
8. Comparison of IgG and F(ab')2 fragments of bispecific anti-RCCxanti-DTIn-1 antibody for pretargeting purposes.
van Schaijk FG; Boerman OC; Soede AC; McBride WJ; Goldenberg DM; Corstens FH; Oosterwijk E
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1089-95. PubMed ID: 15902440
[TBL] [Abstract][Full Text] [Related]
9. A 3-step pretargeting strategy to image infection.
Boerman OC; van Eerd J; Oyen WJ; Corstens FH
J Nucl Med; 2001 Sep; 42(9):1405-11. PubMed ID: 11535733
[TBL] [Abstract][Full Text] [Related]
10. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
11. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations.
Steffens MG; Oosterwijk E; Kranenborg MH; Manders JM; Debruyne FM; Corstens FH; Boerman OC
J Nucl Med; 1999 May; 40(5):829-36. PubMed ID: 10319758
[TBL] [Abstract][Full Text] [Related]
15. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
16. Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates.
Patil V; Gada K; Panwar R; Varvarigou A; Majewski S; Weisenberger A; Ferris C; Tekabe Y; Khaw BA
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):824-39. PubMed ID: 22302089
[TBL] [Abstract][Full Text] [Related]
17. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
18. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225.
Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C
J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869
[TBL] [Abstract][Full Text] [Related]
19. Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies.
Klivényi G; Schuhmacher J; Patzelt E; Hauser H; Matys R; Moock M; Regiert T; Maier-Borst W
J Nucl Med; 1998 Oct; 39(10):1769-76. PubMed ID: 9776285
[TBL] [Abstract][Full Text] [Related]
20. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
